Evropská unie - čeština - EMA (European Medicines Agency)

accord healthcare s.l.u. - metformin hydrochloride, vildagliptin - diabetes mellitus, typ 2 - léky užívané při diabetu - vildagliptin/metformin hydrochloride accord is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:- in patients who are inadequately controlled with metformin hydrochloride alone. - in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. - in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 a 5. 1 pro dostupné údaje o různých kombinacích).

Evropská unie - čeština - EMA (European Medicines Agency)

novartis europharm limited - vildagliptin, metformin hydrochloridu - diabetes mellitus, typ 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - icandra is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 a 5. 1 pro dostupné údaje o různých kombinacích).

Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

krka, d.d., novo mesto, novo mesto array - 17128 vildagliptin; 2418 metformin-hydrochlorid - potahovaná tableta - 50mg/1000mg - metformin a vildagliptin

Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

krka, d.d., novo mesto, novo mesto array - 17128 vildagliptin; 2418 metformin-hydrochlorid - potahovaná tableta - 50mg/850mg - metformin a vildagliptin

Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

g.l. pharma gmbh, lannach array - 17128 vildagliptin; 2418 metformin-hydrochlorid - potahovaná tableta - 50mg/1000mg - metformin a vildagliptin

Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

g.l. pharma gmbh, lannach array - 17128 vildagliptin; 2418 metformin-hydrochlorid - potahovaná tableta - 50mg/850mg - metformin a vildagliptin

Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

belupo lijekovi i kozmetika, d.d., koprivnica array - 17128 vildagliptin; 2418 metformin-hydrochlorid - potahovaná tableta - 50mg/1000mg - metformin a vildagliptin

Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

belupo lijekovi i kozmetika, d.d., koprivnica array - 17128 vildagliptin; 2418 metformin-hydrochlorid - potahovaná tableta - 50mg/850mg - metformin a vildagliptin

Evropská unie - čeština - EMA (European Medicines Agency)

novartis europharm limited - vildagliptin, metformin hydrochloridu - diabetes mellitus, typ 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - eucreas is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control.

Evropská unie - čeština - EMA (European Medicines Agency)

novartis europharm limited  - vildagliptin, metformin hydrochloridu - diabetes mellitus, typ 2 - léky užívané při diabetu - zomarist is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate.